Robert King - SciClone Pharmaceuticals President
President
Dr. Robert S. King, Ph.D. is no longer Senior Vice President Product Development and Supply Chain of SciClone Pharmaceuticals Inc., effective as of January 18, 2017. He joined SciClone in 2011 and serves as Senior Vice President, Product Development and Supply Chain. Prior to joining SciClone, from 2006 to 2011, Dr. King served as Vice President, Product Development and Manufacturing at Bayhill Therapeutics. Prior to Bayhill, from 1993 to 2006, Dr. King was VP, Product Development and Manufacturing at Rinat Neuroscience Corporation
| Age | 49 |
| Professional Marks | Ph.D |
| Phone | 650 358-3456 |
| Web | www.sciclone.com |
Robert King Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert King against SciClone Pharmaceuticals stock is an integral part of due diligence when investing in SciClone Pharmaceuticals. Robert King insider activity provides valuable insight into whether SciClone Pharmaceuticals is net buyers or sellers over its current business cycle. Note, SciClone Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell SciClone Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert King over two weeks ago Acquisition by Robert King of 5887 shares of Corteva subject to Rule 16b-3 |
SciClone Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.16 % which means that it generated a profit of $0.16 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.19 %, meaning that it created $0.19 on every $100 dollars invested by stockholders. SciClone Pharmaceuticals' management efficiency ratios could be used to measure how well SciClone Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 2.73 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. SciClone Pharmaceuticals has a current ratio of 8.19, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist SciClone Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, SciClone Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like SciClone Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for SciClone to invest in growth at high rates of return. When we think about SciClone Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Martin Loeser | Silvercrest Asset Management | N/A | |
| David Saks | AmTrust Financial Services | 56 | |
| Vic Yodong | P10 Inc | N/A | |
| Stephen Ungar | AmTrust Financial Services | 60 | |
| J McCarthy | Bank of New | 51 | |
| David Strauss | P10 Inc | 58 | |
| Michael Grisius | Saratoga Investment Corp | 60 | |
| Ronald Pipoly | AmTrust Financial Services | 56 | |
| Senthil Kumar | Bank of New | 58 | |
| James Wiener | Bank of New | 51 | |
| Karen Keegans | P10 Inc | 49 | |
| Michael Santomassimo | Bank of New | 43 | |
| Guillermo Bichara | P10 Inc | 42 | |
| Michael Toledo | P10 Inc | 53 | |
| Elizabeth Hirsch | P10 Inc | 61 | |
| Joan VeneciaFabul | P10 Inc | N/A | |
| Richard Brueckner | Bank of New | 64 | |
| Jonas Santos | P10 Inc | N/A | |
| Lester Owens | Bank of New | 61 | |
| Kevin McCarthy | Bank of New | 52 | |
| Emily Portney | Bank of New | 52 | |
Management Performance
| Return On Equity | 0.19 | |||
| Return On Asset | 0.16 |
SciClone Pharmaceuticals Leadership Team
Elected by the shareholders, the SciClone Pharmaceuticals' board of directors comprises two types of representatives: SciClone Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SciClone. The board's role is to monitor SciClone Pharmaceuticals' management team and ensure that shareholders' interests are well served. SciClone Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SciClone Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Meng, VP of Compliance and General Counsel | ||
| Richard Hawkins, Independent Director | ||
| Gregg Lapointe, Independent Director | ||
| Hong Zhao, CEO of China Operations | ||
| Wilson Cheung, CFO, Sr. VP of Fin. and Secretary | ||
| Nancy Chang, Director | ||
| Anthony Lapointe, Independent Director | ||
| Lan Xie, VP of Fin. and CFO of China Operations | ||
| Raymond Low, Vice President - Finance, Controller | ||
| Robert King, Senior Vice President - Product Development and Supply Chain | ||
| Simon Li, Independent Director | ||
| Jon Saxe, Independent Chairman of the Board | ||
| Friedhelm Blobel, CEO and President Executive Director and Member of Bus. Devel. Committee |
SciClone Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SciClone Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | |||
| Return On Asset | 0.16 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 25.82 % | |||
| Current Valuation | 422 M | |||
| Shares Outstanding | 52.19 M | |||
| Shares Owned By Insiders | 10.03 % | |||
| Shares Owned By Institutions | 79.96 % | |||
| Number Of Shares Shorted | 1.21 M | |||
| Price To Earning | 13.75 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in SciClone Stock
If you are still planning to invest in SciClone Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SciClone Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |